The Image-guided Biopsy market size was USD 4.01 billion in 2023 and is expected to reach USD 6.98 billion by 2032 and grow at a CAGR of 6.35% over the forecast period of 2024-2032. This report provides comprehensive insights into the Image-guided Biopsy Market, highlighting key trends such as the rising volume of biopsy procedures due to increasing cancer prevalence and advancements in imagmagneting technologies. It examines the adoption of AI and robotics in biopsy guidance, along with the growing preference for outpatient and ambulatory surgical centers. The study analyzes reimbursement trends, healthcare spending, and the economic impact of image-guided biopsies compared to conventional techniques. Additionally, it covers technological adoption rates across MRI, CT, and ultrasound-guided procedures, along with regulatory approvals and clinical trials. The report also explores patient outcomes, demonstrating improved accuracy and reduced complications. Furthermore, it provides insights into the increasing integration of AI-assisted diagnostic imaging and robotic biopsy systems.
North America dominated the image-guided biopsy market in the U.S., accounting for 71% of the overall share, owing to advanced healthcare infrastructure, high adoption of sophisticated imaging technologies, and presence of key players in the region, as per the earlier aspect. Not only does this country have a well-established reimbursement infrastructure, which encourages the hospitals and diagnostic centers to embrace advanced biopsy procedures. In addition, government initiation in funding towards cancer research & advancement of imaging mechanisms in coordination with fast implementation of AI in performing the biopsy processes accentuates the market expansion. Minimally invasive procedure preference and the presence of extensive specialty clinics in the region have enabled the U.S. to remain on the top.
Drivers
Rising cancer prevalence and increasing demand for minimally invasive diagnostic techniques propel the image-guided biopsy market growth.
The growing global burden of cancer, particularly breast, lung, and prostate cancer, is significantly driving the demand for image-guided biopsy procedures. According to the World Health Organization (WHO), cancer cases are expected to rise by over 50% by 2040, increasing the need for early and accurate diagnostic techniques. Image-guided biopsies provide higher precision, minimal invasiveness, and reduced recovery time compared to conventional surgical biopsy methods, making them a preferred choice among healthcare providers. Additionally, technological advancements such as AI-assisted imaging and robotic-guided biopsy systems are enhancing accuracy and efficiency, further fueling market growth. Governments and healthcare agencies are also expanding reimbursement policies to support the adoption of advanced diagnostic imaging techniques, further bolstering market expansion. The shift towards outpatient and ambulatory surgical centers further supports the increased adoption of these procedures.
Restraint:
High Costs associated with image-guided biopsy procedures and limited access to advanced imaging technologies in developing regions hinder market growth.
One of the major restraints affecting the growth of the image-guided biopsy market is the high cost associated with advanced imaging systems such as MRI, CT, and ultrasound-guided biopsy procedures. The initial investment in imaging infrastructure, coupled with the expenses of trained radiologists and interventional specialists, significantly increases the overall cost of the procedure. This poses a major challenge, particularly in low- and middle-income countries where access to high-end imaging technology remains limited. Additionally, reimbursement policies in many regions do not fully cover the costs of advanced diagnostic techniques, leading to financial constraints for both healthcare providers and patients. The lack of skilled professionals trained in handling sophisticated imaging technologies further limits widespread adoption, restricting market growth in certain regions, particularly in rural and underdeveloped healthcare systems.
Opportunity:
Technological advancements in AI-driven imaging and robotic-assisted biopsy procedures create new growth opportunities in the market.
The integration of artificial intelligence (AI) and robotics in biopsy procedures is opening new avenues for market expansion. AI-driven imaging analysis enhances the accuracy and speed of tumor detection, reducing the chances of false negatives and improving overall diagnostic efficiency. Robot-assisted biopsy procedures provide superior precision, reducing human error and improving patient outcomes. Major players are increasingly investing in AI-powered imaging solutions that assist in real-time decision-making and automated tumor segmentation. Additionally, the rising adoption of telemedicine and remote diagnostics is further expanding access to image-guided biopsy procedures, particularly in underserved regions. The growing collaboration between healthcare institutions and technology companies to develop next-generation biopsy solutions is expected to drive market growth, offering significant opportunities for innovation and investment.
Challenge:
Regulatory approvals and stringent compliance requirements pose challenges to the commercialization of image-guided biopsy devices and technologies.
The image-guided biopsy market faces challenges due to stringent regulatory approval processes and compliance requirements across different regions. Medical imaging devices and biopsy systems must undergo rigorous clinical trials and obtain approvals from regulatory bodies such as the U.S. FDA, the European Medicines Agency (EMA), and other global health authorities. The long approval timelines and high costs associated with regulatory compliance often delay the commercialization of innovative biopsy technologies. Additionally, variations in regulatory frameworks across different countries create complexities for manufacturers seeking global market expansion. Ensuring compliance with data security and patient safety standards, particularly in AI-integrated biopsy systems, further adds to the challenges. Companies must invest significant time and resources in meeting these regulatory requirements, which can slow down market entry and limit the widespread adoption of new biopsy solutions.
By Process
The core needle held the largest market share, around 52%, in 2023. It is extensively used for diagnosing cancer, including breast cancer, prostate cancer, and lung cancer. CNB strikes a good balance between accuracy and limits on invasiveness, obtaining bigger tissue samples than fine needle aspiration (FNA) but less invasive than surgical biopsies. Especially for breast cancer diagnosis, ASBrS guidelines recommended the use of CNB as the standard diagnostic method. Image-guided techniques, including ultrasound and MRI-assisted core needle biopsy, have played a vital role in limiting complications and increasing accuracy. A growing trend of moving away from inpatient and towards outpatient and ambulatory settings, when paired with beneficial reimbursement policies, has driven the segment’s dominance. In addition, CNB has high-reliability histopathological results at a low cost, establishing it as a leader in the market.
By Image Guided Technology
Ultrasound-guided biopsy held the largest market share, around 38%, in 2023. It is owing to its increasingly prevalent use in combination with that in combination with low economic cost, and image-guided biopsy in ultrasound is seen as the preferred method with real-time imaging capabilities. Owing to widespread use in the detection of breast, thyroid gland, liver, and prostate cancers and other soft tissue disorders, this modality is extensively adopted worldwide. Ultrasound provides a non-invasive and radiation-free procedure compared with MRI and CT-enhanced procedures, making it safer and more ideal for repeated use. It is also much less expensive compared to MRI and CT, driving growing implementation — especially in developing regions with limited healthcare infrastructure. Ultrasound improves diagnostic accuracy, reduces the risk of complications, and increases precision in needle placement by providing real-time imaging capabilities.
By End User
Hospitals and clinics held the largest market share at around 38% in 2023. This is owing to their advanced imaging infrastructure, large patient inflow, and availability of specialized healthcare professionals. These centers provide a full spectrum of diagnostic and therapeutic services, and they are the go-to for complicated biopsy biopsies that need MRI, CT, or ultrasound guidance. Higher reimbursement rates and more government funding mean that hospitals have the resources to invest in the latest and greatest biopsy technologies. Moreover, the growing incidence of cancer along with chronic diseases is also catalyzing demand for biopsy as it is performed in hospital settings to provide integrated patient care led by the multidisciplinary team. The proficiency of on-site expert support helps the image-guided biopsy be more accurate and successful, a role that includes expert radiologists, oncologists, and interventional specialists. Thus, hospitals and clinics remain the primary driver of the market, owing to better capabilities, experience level, and access to patients.
North America held the largest market share at around 41% in 2023. This is owing to well-established healthcare infrastructure, the presence of major market players in the region, and high adoption of advanced imaging technologies that are driving growth of the image-guided biopsy market in the region. The region is home to major government investments for cancer research and research in diagnostic imaging, including multiple programs funded by the National Cancer Institute (NCI). Rising cancer cases, especially of breast, lung, and prostate cancers, are fuelling the need for accurate biopsy methods. Further, the U.S. and Canada provide extensive health coverage that has opted to reimburse for biopsy techniques, which drove hospitals and diagnostic centers to adopt advanced biopsy techniques. The technological advancement of AI-assisted imaging, robotic biopsy systems, and minimally invasive biopsy techniques has driven the global biopsy market. In addition, with a solid regulatory system and early FDA clearances in well-defined clinical trial programs, North America has strengthened its dominance in the worldwide image-guided biopsy market.
Europe held a significant market share in 2023. This is due to more advanced health care systems, broad acceptance of precision diagnostics, and well-established government support for cancer screening programs. In countries like Germany, France, and the U.K., the favorable reimbursement policies of the reimbursement agencies over the recent years have encouraged hospitals and diagnostic centers to invest in high-end imaging technologies in their clinic setups since the national cancer control programs have advocated the urgent requirement for state-of-the-art imaging technologies. Europe leads the way in the world of medical research, with leading universities and research institutes (such as the University of Cambridge) paving the way to innovations in AI-assisted imaging and the use of minimally invasive biopsies. Moreover, the region's leading market share can be attributed to the presence of key market players and early approvals from the European Medicines Agency (EMA).
Ethicon Endo-Surgery: (ENDOPOUCH Retrieval Pouch, ENDOLOOP Ligature)
Intact Medical Corporation: (Intact Breast Lesion Excision System, Intact Excise)
Galini SRL: (Galini Biopsy Needle, Galini Coaxial Needle)
Hologic Inc.: (Brevera Breast Biopsy System, Eviva Breast Biopsy System)
Leica Biosystems Nussloch GmbH: (Mammotome Elite Biopsy System, Mammotome Revolve Biopsy System)
C. R. Bard, Inc.: (Mission Biopsy Instrument, Vacora Biopsy System)
Becton, Dickinson and Company: (BD Vacutainer Biopsy Needle, BD Temno Biopsy Device)
Argon Medical Devices: (SuperCore Biopsy Instrument, Tru-Core II Biopsy Needle)
Cook Medical Incorporated: Quick-Core Biopsy Needle, EchoTip ProCore Endobronchial Ultrasound Needle)
Encapsule Medical Devices LLC (Encapsule Biopsy System, Encapsule Core Biopsy Needle)
Siemens Healthineers: (ACUSON S2000 Ultrasound System, Mammomat Inspiration Biopsy Unit)
Philips Healthcare: Affiniti 70 Ultrasound System, MicroDose SI Mammography System)
GE Healthcare: (Invenia ABUS, Senographe Pristina)
Canon Medical Systems (Aplio i-series Ultrasound, Celesteion PET/CT System)
Fujifilm Holdings Corporation (ARIETTA 850 Ultrasound, ASPIRE Cristalle Mammography System)
Carestream Health: (DRX-Ascend System, DRX-Revolution Mobile X-ray System)
Hitachi Medical Systems: (ARIETTA 70 Ultrasound, Supria CT Scanner)
Medtronic: (O-arm Surgical Imaging System, StealthStation Surgical Navigation)
Boston Scientific: (LithoVue Single-Use Digital Flexible Ureteroscope, SpyGlass DS Direct Visualization System)
Stryker Corporation (NAV3i Surgical Navigation Platform, iSuite Integrated Operating Room)
In March 2024, Medtronic introduced the Fusion Biopsy System, a robotic-assisted platform that enhances prostate biopsy precision by incorporating advanced imaging and AI technology.
In February 2024, Hologic launched the Selenia Dimensions 3D Mammography System, designed to enhance breast cancer detection with advanced biopsy technology and improved imaging capabilities.
In September 2024, Koelis collaborated with DeepHealth to integrate AI-powered prostate MRI software into its Trinity 3D Ultrasound Platform, streamlining prostate MRI analysis and enabling seamless MRI-US fusion for biopsy and treatment.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD4.01 Billion |
| Market Size by 2032 | USD 6.98 Billion |
| CAGR | CAGR of6.35 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Process (Vacuum, Assisted Biopsy, Core Needle, Fine Needle) • By Technology (MRI Guided, Ultrasound Guided, Mammography, CT, X-Ray) • By End User (Hospitals And Clinics, Ambulatory Surgical Centes, Research and Academic Institutes) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Ethicon Endo-Surgery, Intact Medical Corporation, Galini SRL, Hologic Inc., Leica Biosystems Nussloch GmbH, C. R. Bard, Inc., Becton, Dickinson and Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC, Siemens Healthineers, Philips Healthcare, GE Healthcare, Canon Medical Systems, Fujifilm Holdings Corporation, Carestream Health, Hitachi Medical Systems, Medtronic, Boston Scientific, Stryker Corporation. |
Ans: The Image-guided Biopsy Market was valued at USD 4.01 Billion in 2023.
Ans: The expected CAGR of the global Image-guided Biopsy Market during the forecast period is 6.35%
Ans: Hospitals & Clinics will grow rapidly in the Image-guided Biopsy Market from 2024-2032.
Ans: Rising cancer prevalence and increasing demand for minimally invasive diagnostic techniques propel the image-guided biopsy market growth.
Ans: North America led the Image-guided Biopsy Market in the region with the highest revenue share in 2023.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Procedure Volume Statistics
5.2 Disease Prevalence & Incidence Rates
5.3 Technological Adoption Data
5.4 Regulatory & Approval Trends
5.5 Cost & Economic Impact
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Image-guided Biopsy Market Segmentation by Process
7.1 Chapter Overview
7.2 Vacuum Assisted Biopsy
7.2.1 Vacuum Assisted Biopsy Market Trends Analysis (2020-2032)
7.2.2 Vacuum Assisted Biopsy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Core Needle
7.3.1 Core Needle Market Trends Analysis (2020-2032)
7.3.2 Core Needle Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Fine Needle
7.4.1 Fine Needle Market Trends Analysis (2020-2032)
7.4.2 Fine Needle Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Image-guided Biopsy Market Segmentation, By Image Guided Technology
8.1 Chapter Overview
8.2 MRI
8.2.1 MRI Market Trends Analysis (2020-2032)
8.2.2 MRI Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Ultrasound
8.3.1 Ultrasound Market Trends Analysis (2020-2032)
8.3.2 Ultrasound Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Mammography
8.4.1 Mammography Market Trends Analysis (2020-2032)
8.4.2 Mammography Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 CT
8.5.1 CT Market Trends Analysis (2020-2032)
8.5.2 CT Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 X-Ray
8.6.1 X-Ray Market Trends Analysis (2020-2032)
8.6.2 X-Ray Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Image-guided Biopsy Market Segmentation, by End-User
9.1 Chapter Overview
9.2 Hospitals and Clinics
9.2.1 Hospitals and Clinics Market Trends Analysis (2020-2032)
9.2.2 Hospitals and Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Ambulatory Surgical Centers
9.3.1 Ambulatory Surgical Centers Market Trends Analysis (2020-2032)
9.3.2 Ambulatory Surgical Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Research and Academic Institutes
9.4.1 Research and Academic Institutes Market Trends Analysis (2020-2032)
9.4.2 Research and Academic Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Image-guided Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.2.4 North America Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.2.5 North America Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.2.6.2 USA Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.2.6.3 USA Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.2.7.2 Canada Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.2.7.3 Canada Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.2.8.2 Mexico Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.2.8.3 Mexico Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Image-guided Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.1.6.2 Poland Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.1.6.3 Poland Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.1.7.2 Romania Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.1.7.3 Romania Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Image-guided Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.4 Western Europe Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.5 Western Europe Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.6.2 Germany Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.6.3 Germany Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.7.2 France Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.7.3 France Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.8.2 UK Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.8.3 UK Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.9.2 Italy Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.9.3 Italy Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.10.2 Spain Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.10.3 Spain Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.13.2 Austria Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.13.3 Austria Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Image-guided Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.4 Asia Pacific Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.5 Asia Pacific Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.6.2 China Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.6.3 China Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.7.2 India Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.7.3 India Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.8.2 Japan Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.8.3 Japan Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.9.2 South Korea Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.9.3 South Korea Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.10.2 Vietnam Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.10.3 Vietnam Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.11.2 Singapore Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.11.3 Singapore Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.12.2 Australia Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.12.3 Australia Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Image-guided Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.1.4 Middle East Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.1.5 Middle East Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.1.6.2 UAE Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.1.6.3 UAE Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Image-guided Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.2.4 Africa Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.2.5 Africa Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Image-guided Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.6.4 Latin America Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.6.5 Latin America Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.6.6.2 Brazil Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.6.6.3 Brazil Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.6.7.2 Argentina Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.6.7.3 Argentina Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.6.8.2 Colombia Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.6.8.3 Colombia Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Image-guided Biopsy Market Estimates and Forecasts, by Process (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Image-guided Biopsy Market Estimates and Forecasts, By Image Guided Technology (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Image-guided Biopsy Market Estimates and Forecasts, by End-User (2020-2032) (USD Billion)
11. Company Profiles
11.1 Ethicon Endo-Surgery
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Intact Medical Corporation
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Galini SRL
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Hologic Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Leica Biosystems Nussloch GmbH
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 C. R. Bard, Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Becton and Dickinson Company
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Argon Medical Devices
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Cook Medical Incorporated
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Encapsule Medical Devices LLC
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Process:
Vacuum Assisted Biopsy
Core Needle
Fine Needle
By Image Guided Technology:
MRI
Ultrasound
CT
X-Ray
By End User:
Hospitals And Clinics
Research and Academic Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Conjunctivitis Treatment Market size was USD 4.2 Billion in 2023 and is expected to Reach USD 6.3 Billion by 2032 and grow at a CAGR of 4.7% over the forecast period of 2024-2032.
The global 3D Printing Medical Devices Market Size was valued at USD 2.69 billion in 2023 and is expected to reach USD 11.46 billion by 2032 and grow at a CAGR of 17.49% by 2024-2032.
The Pregnancy Pillow Market size was estimated at USD 0.73 billion and is poised to reach at USD 1.02 billion by 2032, at a CAGR of 3.83% from 2024-2032.
Airway Disease Treatment Market was valued at $ 2.23 billion in 2023 and is expected to reach $ 3.54 billion by 2032, growing at a CAGR of 5.29% from 2024-2032.
The Small Animal Imaging (In Vivo) Market Size was valued at USD 1.16 billion in 2023 and is expected to reach USD 2.27 billion by 2032 and grow at a CAGR of 7.76% over the forecast period 2024-2032.
The Angioplasty Balloon Market size was estimated at USD 3.05 billion in 2023 and will hit USD 4.18 billion by 2031 growing at a CAGR of 4.01% by 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
